54419-23-7

Basic information

• Product Name: PROPIOPHENONE-2',3',4',5',6'-D5
• Synonyms: PROPIOPHENONE-2',3',4',5',6'-D5;PROPIOPHENONE (RING-D5);Propiophenone-d5 (ring-D5);Propiophenone--d5;1-(2,3,4,5,6-pentadeuteriophenyl)propan-1-one
• CAS NO: 54419-23-7
• Molecular Formula: C₉H₁₀O
• Molecular Weight: 139.21
• Mol File: 54419-23-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 103 °C(Press: 23 Torr)
• Appearance: /
• CAS DataBase Reference: PROPIOPHENONE-2',3',4',5',6'-D5(CAS DataBase Reference)
• NIST Chemistry Reference: PROPIOPHENONE-2',3',4',5',6'-D5(54419-23-7)
• EPA Substance Registry System: PROPIOPHENONE-2',3',4',5',6'-D5(54419-23-7)

Safety Data

• Hazardous Substances Data: 54419-23-7(Hazardous Substances Data)

Usage

Description

PROPIOPHENONE-2',3',4',5',6'-D5, also known as Propiophenone-d5, is a deuterated analogue of Propiophenone (P827900), an aryl ketone derived from hydrocarbons. It is characterized by the presence of deuterium atoms (D) at the 2', 3', 4', 5', and 6' positions, which distinguishes it from its non-deuterated counterpart. Propiophenone-d5 is utilized in various applications due to its unique properties, including its stability and the ability to serve as a labeled compound for research purposes.

Uses

Used in Pharmaceutical Industry:
PROPIOPHENONE-2',3',4',5',6'-D5 is used as a labeled compound for the synthesis and analysis of pharmaceutical and organic compounds. The incorporation of deuterium atoms enhances the compound's stability and allows for more accurate tracking and identification during chemical reactions and biological processes.
Used in Perfumery:
In the perfume industry, PROPIOPHENONE-2',3',4',5',6'-D5 is used as a labeled analogue of Propiophenone for the preparation of fragrances. The deuterium labeling provides a means to study the compound's behavior in the complex mixtures found in perfumes, potentially leading to improved formulations and understanding of scent interactions.
Used in Neurochemistry Research:
PROPIOPHENONE-2',3',4',5',6'-D5 is employed as a labeled analogue in the preparation of neurochemical compounds, such as ephedrines. The deuterium labeling aids in the study of these compounds' interactions with the nervous system, potentially contributing to the development of new treatments for neurological disorders.
Overall, PROPIOPHENONE-2',3',4',5',6'-D5 is a versatile compound with applications in various industries, including pharmaceuticals, perfumery, and neurochemistry research. Its deuterium labeling makes it a valuable tool for enhancing the understanding and development of new products and treatments.

Upstream product

• 1076-43-3 benzene-d6 
• 79-03-8 propionyl chloride 

Downstream Products

• 119458-27-4 [2H5]5-ethyl-5-phenyl-hydantoin 
• 69262-55-1 N-(<α,α-(2)H2>benzyl)-N-(1-<(2)H5>benzoylethyl)-N,N-dimethylammonium bromide 
• 345945-19-9 N-methyl-N-(1-<(2)H5>phenylethyl)-N-(1-<(2)H5>benzoylethyl)amine 
• 87258-67-1 2-dimethylamino-1-<(2)H5>phenylpropan-1-one 
• 78800-79-0 β-methylstyrene-d5 cation 
• 78800-79-0 1-phenyl-d5-1-propene 
• 87258-66-0 2-bromo-1-<(2)H5>phenylpropan-1-one 
• 78800-80-3 1-phenyl-d5-1-propanol 

Relevant articles and documents

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

The thienopyridine derivatives ticlopidine and clopidogrel are inhibitors of ADP-induced platelet aggregation. Pharmacological activity of these prodrugs depends on cytochrome P450 (P450)-dependent oxidation to the active antithrombotic agent. In this study, we investigated the interaction potential of clopidogrel and ticlopidine by using human liver microsomes and recombinantly expressed P450 isoforms. Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency, Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency. Inhibition of CYP2B6 was time- and concentration-dependent, and as shown by dialysis experiments, it was irreversible and dependent on NADPH, suggesting a mechanism-based mode of action. Inactivation was of nonpseudo-first-order type with maximal rates of inactivation (K inact) for clopidogrel and ticlopidine in microsomes (recombinant CYP2B6) of 0.35 (1.5 min-1) and 0.5 min-1 (0.8 min -1), respectively, and half-maximal inactivator concentrations (KI) were 0.5 μM (1.1 μM) for clopidogrel and 0.2 μM (0.8 μM) for ticlopidine. Inhibition was attenuated by the presence of alternative active site ligands but not by nucleophilic trapping agents or reactive oxygen scavengers, further supporting mechanism-based action. A chemical mechanism is discussed based on the known metabolic activation of clopidogrel and on the finding that hemoprotein integrity of recombinant CYP2B6 was not affected by irreversible inhibition. These results suggest the possibility of drug interactions between thienopyridine derivates and drug substrates of CYP2B6 and CYP2C19.

Absorption Spectra and Photochemical Rearrangements in Phenylalkene Cations in Solid Argon

Matrix photoionization experiments with phenylalkenes produced and trapped the parent molecular cations in solid argon at 20 K.In the substituted styrene cation cases, structure was resolved in red and ultraviolet absorption bands and assigned to Ph-C stretching and Ph-C=C bending modes.Molecular ion rearrangements were observed during sample formation and upon the photolysis of the cold sample; allylbenzene cation rearranged to β-methylstyrene cation and indan cation with 290 nm irradiation.The matrix absorption bands were substantially sharper than photodissociati on spectra, which suggests that excess internal energy may contribute substantially to the bandwidth of gaseous molecular ions produced by electron impact.